LOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / March 28, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (Nasdaq:LOBO) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, March 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

• LOBO EV: https://www.redchip.com/assets/access/lobo_access
• Biotricity: https://www.redchip.com/assets/access/btcy_access

In an exclusive interview, Harry Schulman, an independent director of LOBO EV, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to provide a corporate update. LOBO EV, headquartered in Wuxi, China, is a pioneering OEM and ODM manufacturer and seller of electric vehicles (EVs), including e-bicycles, e-mopeds, e-tricycles, and electric off-highway four-wheeled shuttles, tailored for various demographics, including mobility solutions for the elderly and disabled. Beyond vehicle manufacturing, LOBO EV offers automobile information and entertainment software development services to industry OEMs. The Company has a proven track record of leveraging advanced technologies in connectivity, multimedia, interactive systems, and artificial intelligence to enhance user experience with affordable, convenient, and enjoyable driving solutions. The Chinese e-bike market, currently valued at $16 billion, is forecasted to nearly double, reaching $31.3 billion in the next five years with a compound annual growth rate (CAGR) of 11.76%, according to Research and Markets. LOBO EV's robust financial performance across its key segments, coupled with the vast market opportunities within China's EV industry, position LOBO EV for significant upside.

In an exclusive interview, Dr. Waqaas Al-Siddiq, Founder, Chairman and CEO of Biotricity, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to provide a corporate update. Biotricity is revolutionizing cardiac care with its cutting-edge remote diagnostic and monitoring solutions that cater to a $35 billion total addressable market opportunity. By integrating advanced hardware and proprietary software, Biotricity has established a new paradigm in cardiac care. The Company's robust technology platform and product ecosystem, featuring FDA-cleared smart cardiac monitors, coupled with a comprehensive cloud ecosystem, ensure seamless management of patient health across all stages of cardiac care. Utilized daily by cardiologists across 34 states and 500 centers, Biotricity has captured an 8% market share in cardiology, bolstered by a remarkable 99.2% retention rate and an LTV/CAC ratio of 9. With its strong technological foundation, clear path to profitability, strategic market positioning, and experienced leadership, Biotricity represents a compelling value proposition for investors seeking to capitalize on the rapidly evolving medtech space.